{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T02:22:55Z","timestamp":1787365375638,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"DOI":"10.1007\/s10822-026-00919-x","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T01:23:23Z","timestamp":1787361803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Computational identification of potential VEGFR2 inhibitors using integrated pharmacophore modeling, QSAR analysis, molecular docking, dynamics simulation, and virtual screening followed by in vitro bioassays"],"prefix":"10.1007","volume":"40","author":[{"given":"Ouafa","family":"Meziani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Ait Kaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad","family":"Ferkous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khairedine","family":"Kraim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faycal","family":"Layachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youcef","family":"Saihi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuba T\u00fcyl\u00fc","family":"K\u00fc\u00e7\u00fckk\u0131l\u0131n\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyhan","family":"T\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"919_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21660","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"919_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm0195-27","volume":"1","author":"J Folkman","year":"1995","unstructured":"Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27\u201330. https:\/\/doi.org\/10.1038\/nm0195-27","journal-title":"Nat Med"},{"key":"919_CR3","doi-asserted-by":"publisher","first-page":"189079","DOI":"10.1016\/j.bbcan.2024.189079","volume":"1879","author":"P Shaw","year":"2024","unstructured":"Shaw P, Dwivedi SKD, Bhattacharya R, Mukherjee P, Rao G (2024) VEGF signaling: role in angiogenesis and beyond. Biochim Biophys Acta Rev Cancer 1879:189079. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189079","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"919_CR4","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/j.cellsig.2007.05.013","volume":"19","author":"K Holmes","year":"2007","unstructured":"Holmes K, Roberts OL, Thomas AM, Cross MJ (2007) Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19:2003\u20132012. https:\/\/doi.org\/10.1016\/j.cellsig.2007.05.013","journal-title":"Cell Signal"},{"key":"919_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298\u2013307. https:\/\/doi.org\/10.1038\/nature10144","journal-title":"Nature"},{"key":"919_CR6","doi-asserted-by":"publisher","first-page":"1307860","DOI":"10.3389\/fphar.2023.1307860","volume":"14","author":"L Wang","year":"2024","unstructured":"Wang L, Liu WQ, Broussy S, Han B, Fang H (2024) Recent advances of anti-angiogenic inhibitors targeting VEGF\/VEGFR axis. Front Pharmacol 14:1307860. https:\/\/doi.org\/10.3389\/fphar.2023.1307860","journal-title":"Front Pharmacol"},{"key":"919_CR7","doi-asserted-by":"publisher","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125\u2013134. https:\/\/doi.org\/10.1056\/NEJMoa060655","DOI":"10.1056\/NEJMoa060655"},{"key":"919_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10456-009-9160-6","volume":"13","author":"KJ Gotink","year":"2010","unstructured":"Gotink KJ, Verheul HM (2010) Anti-angiogenic tyrosine kinase inhibitors: What is their mechanism of action? Angiogenesis 13:1\u201314. https:\/\/doi.org\/10.1007\/s10456-009-9160-6","journal-title":"Angiogenesis"},{"key":"919_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10456-014-9420-y","volume":"17","author":"NS Vasudev","year":"2014","unstructured":"Vasudev NS, Reynolds AR (2014) Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17:471\u2013494. https:\/\/doi.org\/10.1007\/s10456-014-9420-y","journal-title":"Angiogenesis"},{"key":"919_CR10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1124\/pr.112.007336","volume":"66","author":"G Sliwoski","year":"2013","unstructured":"Sliwoski G, Kothiwale S, Meiler J, Lowe EW Jr (2013) Computational methods in drug discovery. Pharmacol Rev 66:334\u2013395. https:\/\/doi.org\/10.1124\/pr.112.007336","journal-title":"Pharmacol Rev"},{"key":"919_CR11","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1007\/s11030-024-10979-6","volume":"29","author":"MN da Rocha","year":"2025","unstructured":"da Rocha MN, de Sousa DS, da Silva Mendes FR, Dos Santos HS, Marinho GS, Marinho MM, Marinho ES (2025) Ligand and structure-based virtual screening approaches in drug discovery: minireview. Mol Divers 29:2799\u20132809. https:\/\/doi.org\/10.1007\/s11030-024-10979-6","journal-title":"Mol Divers"},{"key":"919_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1021\/ci049885e","volume":"45","author":"G Wolber","year":"2005","unstructured":"Wolber G, Langer T (2005) LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 45:160\u2013169. https:\/\/doi.org\/10.1021\/ci049885e","journal-title":"J Chem Inf Model"},{"key":"919_CR13","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/978-3-319-27282-5_54","volume":"9","author":"B Rasulev","year":"2016","unstructured":"Rasulev B (2016) Recent developments in 3D QSAR and molecular docking studies of organic and nanostructures. Handb Comput Chem 9:2133\u20132161. https:\/\/doi.org\/10.1007\/978-3-319-27282-5_54","journal-title":"Handb Comput Chem"},{"key":"919_CR14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455\u2013461. https:\/\/doi.org\/10.1002\/jcc.21334","journal-title":"J Comput Chem"},{"key":"919_CR15","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","volume":"99","author":"SA Hollingsworth","year":"2018","unstructured":"Hollingsworth SA, Dror RO (2018) Molecular dynamics simulation for All. Neuron 99:1129\u20131143. https:\/\/doi.org\/10.1016\/j.neuron.2018.08.011","journal-title":"Neuron"},{"key":"919_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.20892\/j.issn.2095-3941.2020.0151","volume":"18","author":"H Ni","year":"2021","unstructured":"Ni H, Guo M, Zhang X, Jiang L, Tan S, Yuan J, Cui H, Min Y, Zhang J, Schlisio S, Ma C, Liao W, Nister M, Chen C, Li S, Li N (2021) VEGFR2 inhibition hampers breast cancer cell proliferation via enhanced mitochondrial biogenesis. Cancer Biol Med 18:139\u2013154. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2020.0151","journal-title":"Cancer Biol Med"},{"key":"919_CR17","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/hep.27236","volume":"60","author":"S Peng","year":"2014","unstructured":"Peng S, Wang Y, Peng H, Chen D, Shen S, Peng B, Chen M, Lencioni R, Kuang M (2014) Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma. Hepatology 60:1264\u20131277. https:\/\/doi.org\/10.1002\/hep.27236","journal-title":"Hepatology"},{"key":"919_CR18","doi-asserted-by":"publisher","first-page":"6003","DOI":"10.3390\/molecules25246003","volume":"25","author":"MS Hijjawi","year":"2020","unstructured":"Hijjawi MS, Abutayeh RF, Taha MO (2020) Structure-based discovery and bioactivity evaluation of novel Aurora-A kinase inhibitors as anticancer agents via docking-based comparative intermolecular contacts analysis (dbCICA). Molecules 25:6003. https:\/\/doi.org\/10.3390\/molecules25246003","journal-title":"Molecules"},{"key":"919_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.cbi.2016.05.023","volume":"254","author":"MA Khanfar","year":"2016","unstructured":"Khanfar MA, Al-Qtaishat S, Habash M, Taha MO (2016) Discovery of potent adenosine A2a antagonists as potential anti-Parkinson disease agents. Non-linear QSAR analyses integrated with pharmacophore modeling. Chem Biol Interact 254:93\u2013101. https:\/\/doi.org\/10.1016\/j.cbi.2016.05.023","journal-title":"Chem Biol Interact"},{"key":"919_CR20","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1021\/jm7009765","volume":"51","author":"MO Taha","year":"2008","unstructured":"Taha MO, Bustanji Y, Al-Ghussein MA, Mohammad M, Zalloum H, Al-Masri IM, Atallah N (2008) Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin. J Med Chem 51:2062\u20132077. https:\/\/doi.org\/10.1021\/jm7009765","journal-title":"J Med Chem"},{"key":"919_CR21","doi-asserted-by":"publisher","first-page":"4241","DOI":"10.1007\/s11030-024-10814-y","volume":"28","author":"R Banat","year":"2024","unstructured":"Banat R, Daoud S, Taha MO (2024) Ligand-based pharmacophore modeling and machine learning for the discovery of potent aurora A kinase inhibitory leads of novel chemotypes. Mol Divers 28:4241\u20134257. https:\/\/doi.org\/10.1007\/s11030-024-10814-y","journal-title":"Mol Divers"},{"key":"919_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10822-021-00435-0","volume":"36","author":"LA Mousa","year":"2022","unstructured":"Mousa LA, Hatmal MM, Taha M (2022) Exploiting activity cliffs for building pharmacophore models and comparison with other pharmacophore generation methods: sphingosine kinase 1 as case study. J Comput Aided Mol Des 36:39\u201362. https:\/\/doi.org\/10.1007\/s10822-021-00435-0","journal-title":"J Comput Aided Mol Des"},{"key":"919_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10822-011-9509-y","volume":"26","author":"R Shahin","year":"2012","unstructured":"Shahin R, Alqtaishat S, Taha MO (2012) Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors. J Comput Aided Mol Des 26:249\u2013266. https:\/\/doi.org\/10.1007\/s10822-011-9509-y","journal-title":"J Comput Aided Mol Des"},{"key":"919_CR24","doi-asserted-by":"publisher","first-page":"10686","DOI":"10.1039\/D2RA00136E","volume":"12","author":"MF Al-Tawil","year":"2022","unstructured":"Al-Tawil MF, Daoud S, Ma\u2019mon MH, Taha MO (2022) Discovery of new Cdc2-like kinase 4 (CLK4) inhibitors via pharmacophore exploration combined with flexible docking-based ligand\/ receptor contact fingerprints and machine learning. RSC Adv 12:10686\u201310700. https:\/\/doi.org\/10.1039\/D2RA00136E","journal-title":"RSC Adv"},{"key":"919_CR25","doi-asserted-by":"publisher","first-page":"6478","DOI":"10.1021\/jm800718k","volume":"51","author":"MO Taha","year":"2008","unstructured":"Taha MO, Dahabiyeh LA, Bustanji Y, Zalloum H, Saleh S (2008) Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors. J Med Chem 51:6478\u20136494. https:\/\/doi.org\/10.1021\/jm800718k","journal-title":"J Med Chem"},{"key":"919_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jmgm.2019.01.011","volume":"88","author":"RF Abutayeh","year":"2019","unstructured":"Abutayeh RF, Taha MO (2019) Discovery of novel Flt3 inhibitory chemotypes through extensive ligand-based and new structure-based pharmacophore modelling methods. J Mol Graph Model 88:128\u2013151. https:\/\/doi.org\/10.1016\/j.jmgm.2019.01.011","journal-title":"J Mol Graph Model"},{"key":"919_CR27","doi-asserted-by":"publisher","first-page":"107615","DOI":"10.1016\/j.jmgm.2020.107615","volume":"99","author":"S Daoud","year":"2020","unstructured":"Daoud S, Taha MO (2020) Pharmacophore modeling of JAK1: a target infested with activity-cliffs. J Mol Graph Model 99:107615. https:\/\/doi.org\/10.1016\/j.jmgm.2020.107615","journal-title":"J Mol Graph Model"},{"key":"919_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2174\/1871520616666160926114416","volume":"17","author":"WA Mera","year":"2017","unstructured":"Mera WA, Alzihlif M, Taha MO, Khanfar MA (2017) Discovery of potent Bruton\u2019s tyrosine kinase inhibitors using ligand based modeling. Anticancer Agents Med Chem 17:265\u2013275. https:\/\/doi.org\/10.2174\/1871520616666160926114416","journal-title":"Anticancer Agents Med Chem"},{"key":"919_CR29","doi-asserted-by":"publisher","unstructured":"Shahin R, Taha MO (2012) Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+\/calmodulin-dependent protein kinase II inhibitory leads. Bioorg Med Chem 20(1):377\u2013400. https:\/\/doi.org\/10.1016\/j.bmc.2011.10.071","DOI":"10.1016\/j.bmc.2011.10.071"},{"key":"919_CR30","doi-asserted-by":"publisher","unstructured":"Taha MO (2012) Mixing pharmacophore modeling and classical QSAR analysis as powerful tool for lead discovery. In: Virtual screening. IntechOpen, London (UK), pp 1\u201316. https:\/\/doi.org\/10.5772\/20993","DOI":"10.5772\/20993"},{"key":"919_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cbi.2016.03.006","volume":"250","author":"NH Aboalhaija","year":"2016","unstructured":"Aboalhaija NH, Zihlif MA, Taha MO (2016) Discovery of new selective cytotoxic agents against Bcl-2 expressing cancer cells using ligand-based modeling. Chem-Biol Interact 250:12\u201326. https:\/\/doi.org\/10.1016\/j.cbi.2016.03.006","journal-title":"Chem-Biol Interact"},{"key":"919_CR32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1006\/jmbi.1997.1203","volume":"272","author":"HA Gabb","year":"1997","unstructured":"Gabb HA, Jackson RM, Sternberg MJ (1997) Modelling protein docking using shape complementarity, electrostatics and biochemical information. J Mol Biol 272:106\u2013120. https:\/\/doi.org\/10.1006\/jmbi.1997.1203","journal-title":"J Mol Biol"},{"key":"919_CR33","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1612::AID-JCC7>3.0.CO;2-M","volume":"19","author":"M Vieth","year":"1998","unstructured":"Vieth M, Hirst JD, Kolinski A, Brooks CL III (1998) Assessing energy functions for flexible docking. J Comput Chem 19:1612\u20131622. https:\/\/doi.org\/10.1002\/(SICI)1096-987X(19981115)19:14%3C1612::AID-JCC7%3E3.0.CO;2-M","journal-title":"J Comput Chem"},{"key":"919_CR34","doi-asserted-by":"publisher","first-page":"104532","DOI":"10.1016\/j.bioorg.2020.104532","volume":"107","author":"IH Eissa","year":"2021","unstructured":"Eissa IH, Ibrahim MK, Metwaly AM, Belal A, Mehany ABM, Abdelhady AA, Elhendawy MA, Radwan MM, ElSohly MA, Mahdy HA (2021) Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma. Bioorg Chem 107:104532. https:\/\/doi.org\/10.1016\/j.bioorg.2020.104532","journal-title":"Bioorg Chem"},{"key":"919_CR35","doi-asserted-by":"publisher","first-page":"e2000219","DOI":"10.1002\/ardp.202000219","volume":"354","author":"K El-Adl","year":"2021","unstructured":"El-Adl K, Ibrahim MK, Khedr F, Abulkhair HS, Eissa IH (2021) N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: design, synthesis, molecular docking, and anticancer evaluation studies. Arch Pharm (Weinheim) 354:e2000219. https:\/\/doi.org\/10.1002\/ardp.202000219","journal-title":"Arch Pharm (Weinheim)"},{"key":"919_CR36","doi-asserted-by":"publisher","first-page":"102988","DOI":"10.1016\/j.bioorg.2019.102988","volume":"89","author":"MK Sobhy","year":"2019","unstructured":"Sobhy MK, Mowafy S, Lasheen DS, Farag NA, Abouzid KAM (2019) 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: design, synthesis and biological evaluation. Bioorg Chem 89:102988. https:\/\/doi.org\/10.1016\/j.bioorg.2019.102988","journal-title":"Bioorg Chem"},{"key":"919_CR37","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1016\/j.bmc.2012.05.068","volume":"20","author":"A Gangjee","year":"2012","unstructured":"Gangjee A, Zhao Y, Ihnat MA, Thorpe JE, Bailey-Downs LC, Kisliuk RL (2012) Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents. Bioorg Med Chem 20:4217\u20134225. https:\/\/doi.org\/10.1016\/j.bmc.2012.05.068","journal-title":"Bioorg Med Chem"},{"key":"919_CR38","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.bmc.2013.01.040","volume":"21","author":"A Gangjee","year":"2013","unstructured":"Gangjee A, Zaware N, Raghavan S, Disch BC, Thorpe JE, Bastian A, Ihnat MA (2013) Synthesis and biological activity of 5-chloro-N4-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents. Bioorg Med Chem 21:1857\u20131864. https:\/\/doi.org\/10.1016\/j.bmc.2013.01.040","journal-title":"Bioorg Med Chem"},{"key":"919_CR39","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.bmc.2012.12.045","volume":"21","author":"A Gangjee","year":"2013","unstructured":"Gangjee A, Namjoshi OA, Yu J, Ihnat MA, Thorpe JE, Bailey-Downs LC (2013) N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents. Bioorg Med Chem 21:1312\u20131323. https:\/\/doi.org\/10.1016\/j.bmc.2012.12.045","journal-title":"Bioorg Med Chem"},{"key":"919_CR40","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.bmcl.2005.12.090","volume":"16","author":"AS Kiselyov","year":"2006","unstructured":"Kiselyov AS, Semenova M, Semenov VV, Milligan D (2006) Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. Bioorg Med Chem Lett 16:1913\u20131919. https:\/\/doi.org\/10.1016\/j.bmcl.2005.12.090","journal-title":"Bioorg Med Chem Lett"},{"key":"919_CR41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-1-4939-9089-4_7","volume":"1939","author":"CG Bologa","year":"2019","unstructured":"Bologa CG, Ursu O, Oprea TI (2019) How to prepare a compound collection prior to virtual screening. Methods Mol Biol 1939:119\u2013138. https:\/\/doi.org\/10.1007\/978-1-4939-9089-4_7","journal-title":"Methods Mol Biol"},{"key":"919_CR42","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1021\/ci100176x","volume":"50","author":"D Fourches","year":"2010","unstructured":"Fourches D, Muratov E, Tropsha A (2010) Trust, but verify: on the importance of chemical structure curation in cheminformatics and QSAR modeling research. J Chem Inf Model 50:1189\u20131204. https:\/\/doi.org\/10.1021\/ci100176x","journal-title":"J Chem Inf Model"},{"key":"919_CR43","doi-asserted-by":"publisher","first-page":"6480","DOI":"10.2174\/0929867326666190614160451","volume":"27","author":"JM Gally","year":"2020","unstructured":"Gally JM, Bourg S, Fogha J, Do QT, Aci-S\u00e8che S, Bonnet P (2020) VSPrep: a KNIME workflow for the preparation of molecular databases for virtual screening. Curr Med Chem 27:6480\u20136494. https:\/\/doi.org\/10.2174\/0929867326666190614160451","journal-title":"Curr Med Chem"},{"key":"919_CR44","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41586-020-2117-z","volume":"580","author":"C Gorgulla","year":"2020","unstructured":"Gorgulla C, Boeszoermenyi A, Wang ZF, Fischer PD, Coote PW, Padmanabha Das KM, Malets YS, Radchenko DS, Moroz YS, Scott DA, Fackeldey K, Hoffmann M, Iavniuk I, Wagner G, Arthanari H (2020) An open-source drug discovery platform enables ultra-large virtual screens. Nature 580:663\u2013668. https:\/\/doi.org\/10.1038\/s41586-020-2117-z","journal-title":"Nature"},{"key":"919_CR45","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1093\/bioinformatics\/btx491","volume":"33","author":"D Lagorce","year":"2017","unstructured":"Lagorce D, Bouslama L, Becot J, Miteva MA, Villoutreix BO (2017) FAF-Drugs4: free ADME-tox filtering computations for chemical biology and early stages drug discovery. Bioinformatics 33:3658\u20133660. https:\/\/doi.org\/10.1093\/bioinformatics\/btx491","journal-title":"Bioinformatics"},{"key":"919_CR46","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/aps.2012.76","volume":"33","author":"WF Mao","year":"2012","unstructured":"Mao WF, Shao MH, Gao PT, Ma J, Li HJ, Li GL, Han BH, Yuan CG (2012) The important roles of RET, VEGFR2 and the RAF\/MEK\/ERK pathway in cancer treatment with sorafenib. Acta Pharmacol Sin 33:1311\u20131318. https:\/\/doi.org\/10.1038\/aps.2012.76","journal-title":"Acta Pharmacol Sin"},{"key":"919_CR47","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1021\/acs.jctc.5b00935","volume":"12","author":"J Lee","year":"2016","unstructured":"Lee J, Cheng X, Swails JM, Yeom MS, Eastman PK, Lemkul JA, Wei S, Buckner J, Jeong JC, Qi Y, Jo S, Pande VS, Case DA, Brooks CL 3rd, MacKerell AD Jr, Klauda JB, Im W (2016) CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field. J Chem Theory Comput 12:405\u2013413. https:\/\/doi.org\/10.1021\/acs.jctc.5b00935","journal-title":"J Chem Theory Comput"},{"key":"919_CR48","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nmeth.4067","volume":"14","author":"J Huang","year":"2017","unstructured":"Huang J, Rauscher S, Nawrocki G, Ran T, Feig M, de Groot BL, Grubm\u00fcller H, MacKerell AD Jr (2017) CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat Methods 14:71\u201373. https:\/\/doi.org\/10.1038\/nmeth.4067","journal-title":"Nat Methods"},{"key":"919_CR49","doi-asserted-by":"publisher","first-page":"8577","DOI":"10.1063\/1.470117","volume":"103","author":"U Essmann","year":"1995","unstructured":"Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG (1995) A smooth particle mesh Ewald method. J Chem Phys 103:8577\u20138593. https:\/\/doi.org\/10.1063\/1.470117","journal-title":"J Chem Phys"},{"key":"919_CR50","doi-asserted-by":"publisher","unstructured":"Hess B, Bekker H, Berendsen HJC, Fraaije JGEM (1997) LINCS: a linear constraint solver for molecular simulations. J Comput Chem 18:1463\u20131472. https:\/\/doi.org\/10.1002\/(SICI)1096-987X(199709)18:12%3C1463::AID-JCC4%3E3.0.CO;2-H","DOI":"10.1002\/(SICI)1096-987X(199709)18:12%3C1463::AID-JCC4%3E3.0.CO;2-H"},{"key":"919_CR51","doi-asserted-by":"publisher","first-page":"014101","DOI":"10.1063\/1.2408420","volume":"126","author":"G Bussi","year":"2007","unstructured":"Bussi G, Donadio D, Parrinello M (2007) Canonical sampling through velocity rescaling. J Chem Phys 126:014101. https:\/\/doi.org\/10.1063\/1.2408420","journal-title":"J Chem Phys"},{"key":"919_CR52","doi-asserted-by":"publisher","first-page":"114107","DOI":"10.1063\/5.0020514","volume":"153","author":"M Bernetti","year":"2020","unstructured":"Bernetti M, Bussi G (2020) Pressure control using stochastic cell rescaling. J Chem Phys 153:114107. https:\/\/doi.org\/10.1063\/5.0020514","journal-title":"J Chem Phys"},{"key":"919_CR53","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","volume":"17","author":"MS Vald\u00e9s-Tresanco","year":"2021","unstructured":"Vald\u00e9s-Tresanco MS, Vald\u00e9s-Tresanco ME, Valiente PA, Moreno E (2021) gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS. J Chem Theory Comput 17:6281\u20136291. https:\/\/doi.org\/10.1021\/acs.jctc.1c00645","journal-title":"J Chem Theory Comput"},{"key":"919_CR54","doi-asserted-by":"publisher","unstructured":"Miller BR 3rd, McGee TD Jr, Swails JM, Homeyer N, Gohlke H, Roitberg AE (2012) MMPBSA.py: an efficient program for end-state free energy calculations. J Chem Theory Comput 8:3314\u20133321. https:\/\/doi.org\/10.1021\/ct300418h","DOI":"10.1021\/ct300418h"},{"key":"919_CR55","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1007\/s11033-020-05306-9","volume":"47","author":"M Farzaneh Behelgardi","year":"2020","unstructured":"Farzaneh Behelgardi M, Zahri S, Gholami Shahvir Z, Mashayekhi F, Mirzanejad L, Asghari SM (2020) Targeting signaling pathways of VEGFR1 and VEGFR2 as a potential target in the treatment of breast cancer. Mol Biol Rep 47:2061\u20132071. https:\/\/doi.org\/10.1007\/s11033-020-05306-9","journal-title":"Mol Biol Rep"},{"key":"919_CR56","doi-asserted-by":"publisher","first-page":"109693","DOI":"10.1016\/j.bioorg.2026.109693","volume":"174","author":"M Zengin","year":"2026","unstructured":"Zengin M, Arafa RK, K\u00fc\u00e7\u00fckk\u0131l\u0131n\u00e7 TT, Tan OU (2026) Targeting VEGFR-2 with piperazine bridged indolin-2-one derivatives. Bioorg Chem 174:109693. https:\/\/doi.org\/10.1016\/j.bioorg.2026.109693","journal-title":"Bioorg Chem"},{"key":"919_CR57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/qsar.200390007","volume":"22","author":"A Tropsha","year":"2003","unstructured":"Tropsha A, Gramatica P, Gombar V (2003) The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb Sci 22:69\u201377. https:\/\/doi.org\/10.1002\/qsar.200390007","journal-title":"QSAR Comb Sci"},{"key":"919_CR58","doi-asserted-by":"publisher","unstructured":"Golbraikh A, Tropsha A (2002) Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. J Comput Aided Mol Des 16:357\u2013369. https:\/\/doi.org\/10.1023\/A:1020869118689","DOI":"10.1023\/A:1020869118689"},{"key":"919_CR59","doi-asserted-by":"crossref","unstructured":"Taha MO (2012) Virtual screening. BoD\u2013Books on Demand, Norderstedt","DOI":"10.5772\/2049"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-026-00919-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-026-00919-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-026-00919-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T01:23:24Z","timestamp":1787361804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-026-00919-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["919"],"URL":"https:\/\/doi.org\/10.1007\/s10822-026-00919-x","relation":{},"ISSN":["1573-4951"],"issn-type":[{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"15 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"207"}}